PatientsVille.com LogoPatientsVille.com

Lymphocytic Gastritis | Esomeprazole Treatment for Patients With Lymphocytic Gastritis

Lymphocytic Gastritis research study

What is the primary objective of this study?

The purpose of this study is to determine whether treatment with esomeprazole alone is able to heal patients with lymphocytic gastritis

Who is eligible to participate?

Inclusion Criteria: - Histologically proven lymphocytic gastritis (IEL > 25/100) - Male or female aged 18 years or older - Signed and written informed consent Exclusion Criteria: - Regular NSAID or aspirin intake - Concomitant medication with antibiotics, bismuth subsalicylate, aminosalicylates - Regular PPI therapy - Treatment with ketoconazole or other CYP3A inhibitors - previous surgery of the stomach - known or suspected hypersensitivity to esomeprazole - Malignant diseases - Concomitant severe diseases - Pregnancy or lactation - Contraindication to take biopsies (Quick < 50%, PTT > 50 s, thrombocytes < 100.000/mm3)

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Lymphocytic Gastritis

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Esomeprazole

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Study Status

Unknown status

Start Date: February 2007

Completed Date: December 2009

Phase: Phase 3

Type: Interventional

Design:

Primary Outcome: The primary objective is to assess the healing rate of

Secondary Outcome: Secondary objective of the study are to evaluate the grade and activity of gastritis before and after

Study sponsors, principal investigator, and references

Principal Investigator: Ahmed Madisch, MD

Lead Sponsor: Technische Universit├Ąt Dresden

Collaborator:

More information:https://clinicaltrials.gov/show/NCT00455754

Discuss Nexium